Page last updated: 2024-10-15
ra xii
Description
RA XII: structure given in first source; isolated from Rubia cordifolia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Rubia | genus | A plant genus of the family RUBIACEAE. The root is a source of red dyes (madder color and 1,2,4-trihydroxy-9,10-anthracenedione) and ANTHRAQUINONES.[MeSH] | Rubiaceae | The Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH] |
| Rubia cordifolia | species | [no description available] | Rubiaceae | The Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH] |
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 156599349 |
| MeSH ID | M0217519 |
Synonyms (6)
| Synonym |
|---|
| ra-xii |
| ra xii |
| bouvardin, 5-(n-methyl-l-tyrosine)-6-(o-beta-d-glucopyranosyl-3-hydroxy-n-methyl-l-tyrosine)- |
| 143343-98-0 |
| 5-(n-methyl-l-tyrosine)-6-(o-beta-d-glucopyranosyl-3-hydroxy-n-methyl-l-tyrosine)-bouvardin |
| DTXSID501347785 |
Bioavailability
| Excerpt | Reference |
|---|
| " However, RA-XII shows low oral bioavailability in rats due to its poor solubility and low permeability." | ( Novel amorphous solid dispersion based on natural deep eutectic solvent for enhancing delivery of anti-tumor RA-XII by oral administration in rats.
Bi, Q; Ding, X; Lai, Z; Liu, M; Tan, N; Tong, X; Wang, Z; Zhu, L, 2021) |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |